Vancomycin
Approved medicineAlso known as Firvanq, Tyzavan, Vancocin, Vancomicina+4 more
Firvanq, Tyzavan, Vancocin, Vancomicina, Vancomycine, Vancocin HCl, Vancomycin Hydrochloride, Vancomycinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: VANCOMYCIN (NDA211962)
Impact of Prophylactic Use of Irrisept Irrigation System for Spinal Instrumentation
Indication expansion: VANCOMYCIN (NDA211962)
Label change: VANCOMYCIN (NDA211962)
Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis.
Indication expansion: VANCOMYCIN (NDA211962)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes6
Journals, researchers & institutions
- The Journal of antimicrobial chemotherapy4
- The New England journal of medicine3
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2
- American journal of surgery1
- Cancer discovery1
- Clinical and translational science1
- Barriere SL2
- Chambers HF2
- Chesnel L2
- Corey GR2
- Cosgrove SE2
- Friedland HD2
- Gorbach S2
- Hopkins A2
- University of Calgary3
- University of California3
- Academic Medical Center1
- Brigham and Women's Hospital1
- Broad Institute of MIT and Harvard1
- Center for Microbiome Innovation1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Vancomycin in the shared literature.
Studied across 4 of the same disease areas as Vancomycin in the shared literature.
Studied across 3 of the same disease areas as Vancomycin in the shared literature.
Studied across 3 of the same disease areas as Vancomycin in the shared literature.
Studied across 3 of the same disease areas as Vancomycin in the shared literature.
Studied across 3 of the same disease areas as Vancomycin in the shared literature.
Studied across 3 of the same disease areas as Vancomycin in the shared literature.
Studied across 2 of the same disease areas as Vancomycin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.